迪哲医药(688192.SH)：肺癌领域多项最新研究成果在2025年世界肺癌大会(WCLC)上公布

Core Insights - The company reported its latest research findings on two innovative lung cancer drugs, Shuwozhe® and GaoRuizhe®, at the 2025 World Lung Cancer Conference (WCLC) [1][2] - Shuwozhe® has been approved in the U.S. as the only oral targeted therapy for EGFR Exon20ins NSCLC, demonstrating significant and durable anti-tumor efficacy with manageable safety [1] - GaoRuizhe® is undergoing ongoing research in combination with anti-PD-1 monoclonal antibodies for advanced NSCLC, showing no dose-limiting toxicities in the dose escalation phase [2] Group 1 - The company presented 11 new studies on Shuwozhe® and GaoRuizhe® in the NSCLC field at WCLC [1][2] - The international multicenter registration clinical study "Wu-Kong1B" for Shuwozhe® showed a favorable benefit/risk ratio for treating EGFR Exon20ins NSCLC [1] - Shuwozhe® received priority review approval in the U.S. in July 2025 based on the "Wu-Kong1B" study [1] Group 2 - GaoRuizhe® is currently in a study that combines it with anti-PD-1 therapy for late-stage NSCLC, with ongoing patient enrollment and data collection [2] - The research on GaoRuizhe® has not observed dose-limiting toxicities during the initial phases [2]